PROTAC BRM degrader-1

• UNSPSC Description:

  PROTAC BRM degrader-1 (compound 17) is a PROTAC-based BRM and BRG1 degrader, with DC50 values of 93 pM and 4.9 nM, respectively[1].

• Target Antigen:

  Epigenetic Reader Domain; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/protac-brm-degrader-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  NC1=C(C=C(C(C=CC=C2)=C2O)N=N1)N3C[C@H](CC4)N(C5=CC=NC(O[C@@H](C6)C[C@H]6OC(CC7)CCN7CCOC8=NOC([C@@H](C(C)C)C(N(C[C@@H]9O)[C@@H](C9)C(N[C@H](C%10=CC=C(C(SC=N%11)=C%11C)C=C%10)C)=O)=O)=C8)=C5)[C@H]4C3

• Molecular Weight:

  1068.29

• References & Citations:

  [1]Berlin M, et al. PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models. J Med Chem. 2024 Jan 5. |[2]Cantley J, Ye X, Rousseau E, et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. Nat Commun. 2022;13(1):6814.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2378051-80-8